If you have been reading about HPLC-UV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-30. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
=== EC 7.2 Catalysing the translocation of inorganic cations and their chelates === This subclass contains translocases that transfer inorganic cations (metal cations). Based on the reaction they're linked to, EC 7.2 can be further classified into:
BOLD-100, or sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)], is a ruthenium-based anti-cancer therapeutic in clinical development. As of February 2024, BOLD-100 was being tested in a Phase 1b/2a clinical trial in 117 patients with advanced gastrointestinal cancers in combination with the chemotherapy regimen FOLFOX. BOLD-100 is being developed by Bold Therapeutics Inc.
There are 203 possible ways that the exchangeability parameters can be restricted to form sub-models of GTR, ranging from the JC69 and F81 models (where all exchangeability parameters are equal) to the SYM model and the full GTR (or REV) model (where all exchangeability parameters are free). The equilibrium base frequencies are typically treated in two different ways: 1) all
In 1986 and 1987, Transkei, a larger, wealthier, and more populous entity, undertook a series of military raids on Ciskei, and attempted to seize control of Ciskei. One of these raids was an attack on leader Lennox Sebe's compound, with the apparent goal of taking him hostage, in order to force a merger of the two Bantustans. Transkei had previously granted sanctuary to Lennox Sebe's estranged brother, Charles, the former head of Ciskei's security forces, who had been imprisoned in Ciskei on charges of sedition, in addition to previously kidnapping Lennox Sebe's son. The South African government ostensibly intervened to warn the Transkei government off. However, during a later meeting of the Truth and Reconciliation Commission, it was revealed that the plan to amalgamate the Transkei and Ciskei into a proposed Xhosaland, as well as the freeing of Charles Sebe from prison, had been carried out by South African security forces linked to the Civil Cooperation Bureau, in order to consolidate an anti-ANC front in the Eastern Cape region, as part of the abortive Operation Katzen.
Sources: en.wikipedia.org
== Partnerships == Dexcom entered into a partnership in 2015 with Google Life Sciences (which subsequently became Verily) to develop the Dexcom G7 Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its new G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. Tandem Diabetes Care received FDA approval in December 2019 for Control-IQ, a closed-loop technology that uses Tandem's t:slim X2 insulin pump and the Dexcom G6 "to automatically increase, decrease, or stop the delivery of insulin in response to the glucose levels of people with Type 1 diabetes." In June 2019, Dexcom announced a collaboration with Companion Medical to enable the exchange of CGM data from Dexcom with insulin data from InPen into both companies' software applications. Dexcom entered into a partnership with Livongo, a digital chronic care management company, in January 2020 to share CGM data from the Dexcom G6 with Livongo's platform. This integration allowed Livongo to incorporate the CGM data along with other patient data. In February 2020, Dexcom and Insulet Corporation signed a non-exclusive, global agreement to combine current and future Dexcom continuous glucose monitoring systems with Insulet's tubeless insulin delivery Pod into the Omnipod Horizon System for automated insulin delivery. This allowed the ability to adjust insulin doses based on Insulet's algorithm or through their smartphone.
The Don Cossack Choir Serge Jaroff was a group of former officers of the Russian Imperial Army who were discovered singing in Çilingir (near Constantinople), where they had fled after the defeat of their army in the Crimea. They made their formal concert debut in Vienna in 1923, led by their founder, conductor and composer, Serge Jaroff. The choir became popular in America, Japan and Europe, touring the world in the 1930s, 40s and 50s, till today. The men, dressed as Cossacks, sang a cappella in a repertory of Russian sacred and secular music, army, folk and art songs. Cossack dancing was eventually added to their programme.
== Applications == Peroxidase can be used for treatment of industrial waste waters. For example, phenols, which are important pollutants, can be removed by enzyme-catalyzed polymerization using horseradish peroxidase. Thus phenols are oxidized to phenoxy radicals, which participate in reactions where polymers and oligomers are produced that are less toxic than phenols. It also can be used to convert toxic materials into less harmful substances. There are many investigations about the use of peroxidase in many manufacturing processes like adhesives, computer chips, car parts, and linings of drums and cans. Other studies have shown that peroxidases may be used successfully to polymerize anilines and phenols in organic solvent matrices. Peroxidases are sometimes used as histological markers. Cytochrome c peroxidase is used as a soluble, easily purified model for cytochrome c oxidase.
2A peptides are a class of 18–22 aa-long peptides, which can induce ribosomal skipping during translation of a protein in a biological cell. These peptides share a core sequence motif of DxExNPGP, and are found in a wide range of viral families. 2A peptides can be introduced artificially to help generate polyproteins from a single ORF, by causing the ribosome to fail at making a peptide bond, and then resume translation. The members of 2A peptides are named after the virus in which they have been first described. For example, F2A, the first described 2A peptide, is derived from foot-and-mouth disease virus. The name "2A" itself comes from the gene numbering scheme of this virus. These peptides are also known as "self-cleaving" peptides, which is a known misnomer, because the missing peptide bond is never synthesized by the ribosome, and is thus not cleaved.
=== Sensory and nervous systems === Although starfish do not have many well-defined sense organs, they do perceive touch, light, temperature, orientation and the status of the water around them. The tube feet, spines and pedicellariae are sensitive to touch. The tube feet, especially those at the tips of the rays, are also sensitive to chemicals, enabling the starfish to detect odour sources such as food. There are eyespots at the ends of the arms, each one made of 80–200 simple ocelli composed of pigmented epithelial cells. Individual photoreceptor cells are present in other parts of their bodies and respond to light. Whether they advance or retreat depends on the species. Traditionally, starfish were thought to lack a centralized brain. Instead, there is a complex nervous system with a nerve ring around the mouth and a radial nerve running along the ambulacral region of each arm parallel to the radial canal. The peripheral nerve system consists of two nerve nets: one in the epidermis and the other in the lining of the coelomic cavity, which are the sensory and motor systems respectively. Neurons passing through the dermis join the two. Both the ring and radial nerves function in movement and sensory. The sensory component is supplied with information from the sensory organs while the motor nerves control the tube feet and musculature. If one arm detects something attractive, it becomes dominant and temporarily over-rides the other arms to initiate movement towards it. Recent genetic evidence, however, suggests that the majority of an echinoderm's body is "all-brain".
Sources: en.wikipedia.org
=== FCPA bribery lawsuits === From 2005 to 2010, Bio-Rad subsidiaries made bribes to foreign government officials, and made other payments intentionally ignoring the high likelihood of bribery. The bribes were estimated to have made $35.1 million profit for Bio-Rad, primarily from sales in Russia, Vietnam, and Thailand:
The history of carbohydrates, to some extent, is the history of sugar cane, which was first grown in New Guinea. The mass cultivation occurred in India where techniques were developed for the isolation of crystalline sugar. Cane sugar and its cultivation reached Europe around the 13th Century and then expanded to the New World, where industrialization occurred. The chemistry and biochemistry of carbohydrates can be traced to 1811. On that year Constantin Kirchhoff discovered that grape sugar (glucose) forms when starch is boiled with acid. The starch industry started the following year. Henri Braconnot discovered in 1819 that sugar is formed through the action of sulfuric acid on cellulose. William Prout, after chemical analyses of sugar and starch by Joseph Louis Gay-Lussac and Thénard, gave this group of substances the group name "saccharine." The term "carbohydrate" was first proposed by German chemist Carl Schmidt in 1844. In 1856, glycogen, a form of carbohydrate storage in animal livers, was discovered by French physiologist Claude Bernard. Emil Fischer received the 1902 Nobel Prize in Chemistry for his work on sugars and purines. For the discovery of glucose metabolism, Otto Meyerhof received the 1922 Nobel Prize in Physiology or Medicine.
== History == Jannik Bjerrum (son of Niels Bjerrum) developed the first general method for the determination of stability constants of metal-ammine complexes in 1941. The reasons why this occurred at such a late date, nearly 50 years after Alfred Werner had proposed the correct structures for coordination complexes, have been summarised by Beck and Nagypál. The key to Bjerrum's method was the use of the then recently developed glass electrode and pH meter to determine the concentration of hydrogen ions in solution. Bjerrum recognised that the formation of a metal complex with a ligand was a kind of acid–base equilibrium: there is competition for the ligand, L, between the metal ion, Mn+, and the hydrogen ion, H+. This means that there are two simultaneous equilibria that have to be considered. In what follows electrical charges are omitted for the sake of generality. The two equilibria are
Russia leather is a water-resistant leather, oiled with birch bark oil after tanning. This leather was a major export good from seventeenth- and eighteenth-century Russia, as the availability of birch bark oil limited its geographical production. The oil impregnation also deterred insect attack and gave a distinctive and pleasant aroma that was seen as a mark of quality in leather. Birch bark tar is also one of the components of Vishnevsky liniment. Birch bark tar oil is an effective repellent of gastropods. The repellent effect lasts about two weeks. The repellent effect of birch bark tar oil mixed with petroleum jelly and applied to a fence can last up to several months. Birch bark tar oil has strong antiseptic properties, owing to a large amount of phenol derivatives and terpenoid derivatives. Birch bark tar oil was used in the eighteenth century alongside civet and castoreum and many other aromatic substances to scent the fine Spanish leather Peau d'Espagne. At the turn of the twentieth century, birch bark tar had become a specialty fragrance material in perfumery as a base note to impart a leathery, smoky note in fragrances, especially from the leather and tobacco genre, and to a lesser extent in Chypres, especially Cuir de Russie perfumes and fragrance bases, typically together with castoreum and isobutyl quinoline. It is used as an ingredient in some soaps, e.g. the scent of Imperial Leather soap, though other tars (i.e. from pine, coal) with an equally phenolic and smoky odour are more commonly used in soaps as a medicating agent.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.